A study published in The Lancet Psychiatry, based on Swedish national health registry data covering more than 160,000 patients with type 2 diabetes, found that semaglutide — the active ingredient in Ozempic and Wegovy — was associated with a 42 percent lower risk of worsening mental illness compared to other diabetes medications. [1] The findings included a 44 percent lower risk of worsening depression, a 38 percent reduction in anxiety, and a 47 percent lower rate of worsening substance use disorders. [2]

The study is observational, not a randomized controlled trial. Swedish researchers compared outcomes in patients prescribed semaglutide against those on other glucose-lowering medications, controlling for age, sex, baseline mental health, and comorbidities. The design identifies associations but cannot establish causation. [1]

That caveat has not stopped the findings from generating intense debate on medical X, where the causation question has become a proxy for a larger argument about what GLP-1 drugs do to the brain.

The mechanistic hypothesis is plausible. GLP-1 receptors are expressed not only in the pancreas and gut but also in brain regions involved in reward processing and mood. [1] Animal studies show GLP-1 receptor agonists can reduce neuroinflammation and increase dopamine signaling — pathways implicated in depression. If semaglutide modulates these pathways directly, the mental health benefits could be pharmacological, not merely downstream effects of weight loss.

The alternative explanation is simpler. People who lose weight, control blood sugar, and feel physically better tend to report better mental health. Weight stigma contributes significantly to depression and anxiety, and its reduction could account for much of the observed benefit. [2]

The study's size makes it harder to dismiss than earlier hints. A 42 percent risk reduction across 160,000 patients, sustained over years, demands either mechanistic explanation or a compelling confounding variable the researchers missed. [1]

The Lancet Psychiatry editorial urged caution, noting that observational registry data cannot substitute for a randomized trial designed to test semaglutide's mental health effects. [1] Such a trial would take years and cost hundreds of millions. Novo Nordisk has not announced plans to conduct one.

What the study does establish is that semaglutide users did not experience the psychiatric harms some early safety signals suggested. The FDA placed semaglutide under review in 2024 after reports of suicidal ideation. [2] The Swedish data found the opposite: lower rates of self-harm and no increase in suicidal behavior. [1]

The question is no longer whether GLP-1 drugs affect mental health. The question is how.

-- KENJI NAKAMURA, Tokyo